CMS(00867): Exclusive rights to the improved new drug ZUNVEYL, which is used for commercial treatment of mild to moderate Alzheimer's disease symptoms.

CMS (00867) announced that on January 8, 2025, the group signed a licensing, cooperation, and distribution agreement with Alpha Cognition Inc. (Alpha) through its wholly-owned subsidiary for the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets) for the treatment of mild to moderate Alzheimer's disease symptoms. According to the agreement, the group has exclusive rights to develop, register, produce, import, export, and commercialize the product in Asia (excluding Japan), Australia, and New Zealand (region), while Alpha retains the right to manufacture and supply within the region. The collaboration is initially for a period of twenty years from the date of the agreement, and will automatically renew every five years unless terminated by either party. The group continues to expand and develop differentiated innovative products. ZUNVEYL, as a next-generation FDA-approved acetylcholinesterase inhibitor, will diversify the group's innovative drug product portfolio and enhance the overall competitive strength of the group. The product can synergize with the group's existing innovative drugs such as Vituo (diazepam nasal spray), original brand drug Dailixin (flupirtine maleate tablets), and the investigational central nervous system product Y-3 in terms of expert network and market resources. With the group's successful commercialization experience and efficient compliance commercialization system, if ZUNVEYL is approved for market launch, it will provide a new medication option for cognitive impairment treatment in Chinese Alzheimer's patients, meeting the clinical demand for drugs with both effectiveness and safety, improving disease diagnosis and treatment practices, benefiting patients, and expected to have a positive impact on the group's performance.